eras-601,cetuximab,pembrolizumab
merck,eli lilly,erasca
['flagshp-1', 'cetuximab', 'eras-601', 'solid tumor']
$eras - erasca presents promising initial phase 1b dose escalation data from flagshp-1 for eras-601 plus cetuximab in patients with advanced solid tumors at the 2023 aacr annual meeting 
Follow for the latest #healthcare #stockmarket tweets. Visit https://t.co/wA5OfUn0Ee to try our powerful investing tools.